Activation of Type III Nitric Oxide Synthase in Astrocytes Following a Neurotropic Viral Infection  by Barna, Maria et al.
VIROLOGY 223, 331–343 (1996)
ARTICLE NO. 0484
Activation of Type III Nitric Oxide Synthase in Astrocytes Following
a Neurotropic Viral Infection
MARIA BARNA,* TAKASHI KOMATSU,* and CAROL S. REISS*,†,‡,1
*Department of Biology, Main Building Room 1009, Mail Stop 5181, 100 Washington Square East and †Center for Neural Science, New York
University, New York, New York 10003; and ‡Kaplan Cancer Center, New York University, New York, New York 10016
Received January 30, 1996; accepted June 26, 1996
Type III nitric oxide synthase (type III NOS), also known as endothelial cell nitric oxide synthase (eNOS or ecNOS or
NOS-3), is a constitutively expressed, calcium- and calmodulin-dependent, isoform of NOS. Its expression has been localized
to endothelial cells and a subset of neurons in the brain. We report here that resident astrocytes of the central nervous
system (CNS) of mice express type III NOS. Following an experimental neurotropic viral infection, the expression of type
III NOS on reactive astrocytes increases substantially, predominately in virally infected regions of the brain. This upregulation
of type III NOS expression is also evident following cytokine treatment in vitro. The intraperitoneal (i.p.) administration of
IL-12, a potent activator of IFN-g and TNF-a production, results in a substantial increase in type III NOS immunoreactivity
in astrocytes. Cytokine-mediated activation of type III NOS is observed in vitro following exposure of a C6 glioma cells,
which constitutively express type III NOS, to IL-12, IFN-g, and TNF-a treatment. We conclude that astrocytes of the murine
CNS express type III NOS, which may be positively regulated by a number of cytokines following viral infection. Type III
NOS expression by astrocytes represents a novel source of nitric oxide in the brain. It may be important in regulating
perfusion and maintaining the blood–brain barrier. Given the intimate association of astrocytes with endothelial cells and
neurons, increased activity of type III NOS following viral infection may be beneficial in inhibition of viral infection in
neighboring cells. q 1996 Academic Press, Inc.
INTRODUCTION NOS has been cloned and is homologous with the mouse
macrophage enzyme (Galea et al., 1993). In addition to
Nitric oxide (NO) is a short-lived gas (Palmer et al.,
the presence of an inducible form of NOS in astrocytes,
1987), which has been implicated in a wide array of bio-
there appears to be a constitutively expressed form in
logical activities (Nathan and Hibbs, 1991; Marletta, 1989;
vivo (Agullo et al., 1995). Murphy has demonstrated thatNathan, 1992; James and Hibbs, 1990). NO is produced
primary rat astrocyte cultures release a vasorelaxing fac-
by a class of nicotinamide adenine dinucleotide phos-
tor which shares many properties of NO, is sensitive to
phate (NADPH)-dependent nitric oxide synthases which
NOS inhibitors, and was subsequently termed astrocyte-
catalyze the conversion of L-arginine and O2 to L-citrulline derived relaxing factor (ADRF) (Murphy et al., 1990, 1991).
and NO (Palmer et al., 1988; Palmer and Moncada, 1989).
We have observed the expression of type II NOS in
At least three distinct isoforms of NOS exist (Knowles microglia following experimental viral inoculation of ve-
and Moncada, 1994; Stuehr and Griffith, 1992). The endo- sicular stomatitis virus (VSV) in mice (Bi et al., 1995a).
thelial (Type III, ecNOS, NOS-3) and neuronal (Type I, Type II NOS induction in CNS has also been shown in
ncNOS, bNOS, NOS-1) forms are constitutively ex- mice infected with mouse hepatitis virus (Sun et al.,
pressed and are calcium- and calmodulin-dependent. 1995), and rats infected with Bornavirus (Akaike et al.,
Type III NOS differs from Type I in its subcellular localiza- 1995). In the present study, we observed that a number
tion, as it is myristylated, and found associated with of resident astrocytes, in discrete areas of the brain posi-
membranes (Busconi and Michel, 1993). An inducible, tively labeled for type III NOS using immunohistochemi-
calcium-independent NOS (iNOS), Type II NOS, was orig- cal staining of frozen sections of uninfected BALB/c
inally described in macrophages. mouse brain tissue. We were interested therefore in de-
Evidence that astrocytes are capable of expressing an termining if expresion of Type III NOS, which was consti-
inducible, calcium-independent NOS (Type II NOS) was tutively found in some astrocytes, would be altered as a
first obtained using primary astroglial cultures (Simmons result of VSV infection.
and Murphy, 1992). More recently, the astrocyte inducible VSV is a single-stranded negative-sense RNA virus
which belongs to the Rhabdovirus family (Wagner, 1987).
When VSV is administered intranasaly to BALB/c mice,1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (212) 995-4015. E-mail Carol.Reiss@nyu.edu. it results in a primary infection of olfactory receptor neu-
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FIG. 1. Expression of type III NOS in resident astrocytes of the murine CNS. (A) Low power magnification of sagitally cut brain tissue. Abbreviations:
OB, olfactory bulb; AOB, accessory olfacotry bulb; RF, rhinal fissure; CC, cerebral cortex; HC, hippocampus; HY, hypothalamus; ZO, zonal layer of
the superior colliculus; VTA, ventral tegmental area; CG, central grey; CB, cerebellum; 4V, 4th ventricle; BS, brain stem. Bar, 2 mm. Serial sections
of three uninfected BALB/c mouse brain tissue were stained with anti-ecNOS polyclonal antibody. (B) High power magnification of two specific
regions, encircled in A. (a) Bar, 10 nM; (b) bar, 15 nM.
rons (Plakhov et al., 1995). The virus is then transmitted using a sucrose gradient. Viral titers were determined
via the olfactory nerve and infects the olfactory bulb (OB) on monolayers of CHO cells as previously described
and finally leads to an acute infection of the CNS (Forger (Forger et al., 1991; Huneycutt et al., 1994).
et al., 1991; Huneycutt et al., 1994; Lundh et al., 1987). Specific pathogen-free male BALB/cAnTac (purchased
Viral titers usually peak 7 – 10 days postinfection (p.i.) from Taconic, Inc., Germantown, NY) mice, 5– 7 weeks
and correlate with mortality. Those mice which survive of age, were used throughout the experiment. Mice were
completely clear the virus by Day 12 p.i. with no obvious lightly anesthetized for 1 min in a closed container con-
longterm damage to the CNS (Forger et al., 1991; Huney- taining Halothane (Halocarbon Lab, North Augusta, SC)
cutt et al., 1994). followed by intranasal infection with 2 1 105 PFU of VSV
We observed a specific increase in type III NOS ex- in a total volume of 0.01 ml administered equally between
pression in astrocytes following VSV infection. In order each nostril, as previously described (Bi et al., 1995a).
to determine if an upregulation in type III NOS could also Three mice each were sacrificed on Days 0 (uninfected
be mediated by an increase in cytokine expression, we control), 1, 1.5, 2, 3, 4, 6, 8, 14, and 22 postinfection.
examined the expression of type III NOS on astrocytes Mice received a lethal overdose of pentobarbital or of
following the i.p. administration of IL-12 in BALB/c mice. ketamine-xylazine, mice were perfused transcardially
The present study revealed a dose-dependent increase with normal saline, and whole brains were removed and
in type III NOS expression in astrocytes in virally infected quick-frozen in isopentane kept on dry ice before being
areas following IL-12 administration. In vitro experiments stored at 0707 until staining, as previously described (Bi
employing a subclone of Rat C6 glial cells which were et al., 1995a).
found to constitutively express type III NOS, revealed that
following incubation with IFN-g, TNF-a, or IL-12, C6 cells
In vivo administration of IL-12released increased levels of nitrite (NO02 , the stable end-
product of NO) into the supernatant, this production was
blocked by NOS inhibitors and is calcium-dependent. One day prior to infection, groups of 10 mice were
Furthermore, this increase in nitrite release following cy- injected daily for 5 days (01 to /3) i.p. with either me-
tokine treatment of C6 cells directly correlates with Type dium alone, 50 ng IL-12, 100 ng IL-12, or 200 ng IL-12
III NOS immunoreactivity. (generously provided by Genetics Institute) per mouse.
At day 4 p.i., mice received a lethal overdose of pentobar-
MATERIALS AND METHODS
bital or of ketamine-xylozine, mice were perfused trans-
Virus and animals cardially with normal saline, and whole brains were re-
moved and quick-frozen in isopentane kept on dry iceVSV, Indiana serotype, San Juan strain, was propa-
gated in Chinese hamster ovary (CHO) cells and purified before being stored at 0707 until staining.
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FIG. 1—Continued
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Immunohistochemical staining dine (DAB) in 0.01% H2O2 for 5 min. Those tissues which
were processed for double staining were washed twice
Brains were sectioned (20 mm sections) in sagittal ori-
in 0.1 M TBS and incubated with respective primary Abs
entation using a cryostat; 20– 30 serial sections of each
for secondary staining for 2 hr at room temperature. Sec-
brain were prepared on subbed slides. In each staining
tions were then washed in 0.1 M TBS twice and then
experiment, brain sections were removed from the
incubated in biotinylated secondary Ab, followed by avi-
freezer and warmed at room temperature for 10 min be- din-biotinylated peroxidase for another 30 min. Sections
fore being fixed in 10% neutral-buffered formalin for 1
were then incubated with a peroxidase substrate, which
min. Sections were then washed twice in 0.1 M Tris-
produced a bluish-gray reaction product (Vector SO Sub-
buffered saline (TBS, ph 7.6), 10 min each. Endogenous
strate kit, Vector Laboratory). Dried sections were then
peroxidase activity was blocked by incubating sections
coverslipped with Permount (Fisher Scientific).
in 0.3% H2O2 in 0.1 M TBS for 20 min. Sections were then
Cell cultureswashed twice in 0.1 M TBS, and background staining
was blocked by preincubation in 1% bovine serum albu- VSV-susceptible C6 rat glioma and NB41A3 neuro-
min (BSA) (Fisher Scientific, Pittsburgh, PA) in 0.1 M TBS blastoma cells were purchased from American Type Cul-
for 45 min. Sections were then incubated with one of the ture Collection. RAW cells were the gift of Ashok Amin,
following primary Abs for 2 hr at room temperature; type Hospital for Joint Diseases and NYU Medical Center. A
III NOS (1:100, rabbit sera, Transduction Laboratory), type subclone of C6 Rat Glial cells, 90% astrocytes (staining
III NOS (1:1000, rabbit sera, ABR), type II NOS (1:25, rabbit with anti-GFAP, Table 1; 6– 10% of the cells in the culture
sera, Transduction Laboratory), type I NOS (1:25, mAb, react with reagents which detect microglia, mac-1, and
Transduction Laboratory), GFAP (1:200, mAb, Sigma iNOS), was cultured in Ham’s F-10 medium, 15% horse
Chemical Co.), mac-1 (1:25, mAb Sigma), and neurofila- serum, and 2.5% heat-inactivated fetal bovine serum
ment-68 (1:100, rabbit sera, Sigma). Sections were (Sigma). Cells were subcultured two to three times weekly.
washed again in 0.1 M TBS twice and then incubated in
Measurement of nitritebiotinylated secondary Ab (ABC kit, Vector Laboratory),
followed by avidin-biotinylated peroxidase for another 30 Concentrations of NO were determined by assaying
its stable end product, NO02 , as previously describedmin. Sections were then incubated with diamino benzi-
FIG. 2. Double-staining of section for GFAP and type III NOS expression. A section from tissue obtained at 2 days p.i. was stained for co-
expression of GFAP and type III NOS. NOS-expressing cells are brown-staining, and GFAP-expressing cells are blue – grey, as described under
Materials and Methods. Double-stained cells appear dark blue – black. Bar, 10 nM.
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(Bredt et al., 1989; Bi and Reiss, 1995). Equal amounts were examined for type III NOS expression. Expression of
type III NOS in astrocytes was verified by double stainingof samples and Greiss reagent (1% sulfanilamide, 0.1%
N-1-naphthyl-ethylene-diamine, 5% H3PO4) (Sigma) were with type III NOS polyclonal Ab and monoclonal anti-GFAP-
mAb (Fig. 2). As early as 24 hr p.i., astrocytes lining theincubated at room temperature for 10 min. The reaction
produced a pink color, which was quantitated at 540 nm glomerular layer of the olfactory bulb (OB) positively labeled
for type III NOS. At 24 hr p.i., astrocytes are not infectedagainst standards in the same buffer on an automated
microplate reader (model EL 309, Bio-Tek, Inc.) and ex- with virus, and VSV infection is exclusively limited to OB
neurons (Huneycutt et al., 1994). There may be communica-pressed as nM.
tion between virally infected neurons and neighboring as-
Cytokine treatment of C6 cells trocytes, which results in type III NOS expression. As the
virus is transmitted from rostral to caudal regions of theC6 cells (5 1 104) were incubated in triplicate, with
brain, there is an increase in the number of type III NOS-medium or 5 ng/ml IFN-g (R&D Systems), TNF-a (R&D
expressing astrocytes in virally infected areas.Systems), or IL-12 (Genetics Insitute), with or without the
Figure 3 compares the NOS type III staining of unin-NOS inhibitor L-NMA (500 mM, Sigma), or with or without
fected and VSV-infected mice in the olfactory bulb atEDTA (100 nM, Sigma) for 72 hr. NO02 concentrations in Days 0 (Fig. 3a) and Day 4 p.i. (Fig. 3b); also shown isthe culture supernatants were determined using the
the staining of the brain stem in uninfected mice (Fig.Greiss reagent as described above. In another experi-
3c) and 8 days p.i. (Fig. 3d). By Day 3 p.i., staining wasment, C6 cells were cultured with medium, IL-2 (Gen-
observed on astrocytes of the OB and accessory olfac-zyme, 5 ng/ml), IL-12, or IFN-g for up to 72 hr with aliquots
tory bulb (AOB) area. At Day 6 p.i., upregulation of typeof supernatant removed from five replicate wells for de-
III NOS expression was visible also on astrocytes of thetermination of NO02 release. C6 cells, NB41A3, and RAW hippocampal formation and caudate putamen. At Day 8cells were also cultured on chamber slides and incu-
p.i., at the height of viral infection, intense type III NOSbated with either IFN-g, TNF-a, or IL-12 for 72 hr. Cham-
immunoreactivity on astrocytes was visible throughoutber slides were dried for 10 min at room temperature
the entire OB, AOB (Fig. 4a), hippocampal formation, ce-before being fixed in 10% neutral-buffered formalin for
rebral cortex, and greater expression on ependymal as-15 min and then processed for immunohistochemical
trocytes of the central gray, fourth ventricle, and brainstaining as described above.
stem (Fig. 3d). A large portion of astrocytes which were
type III NOS-positive, were located along blood vesselsRESULTS
(Fig. 4b). A decrease in type III NOS expression was
evident at 14 days p.i. and resembled uninfected brainResident astrocytes of the murine CNS express type
tissue at 22 days p.i.III NOS
Immunohistochemical analysis of uninfected BALB/c
Type III NOS expression following i.p. administrationmouse brain tissue revealed that resident astrocytes
of IL-12stained for type III NOS in discrete areas of the brain. In
sagittal sections of mouse brain tissue examined under IL-12 is a heterodimer of p35 and p40 subunits
the light microscope at low magnification, distribution of (Schoenhaut et al., 1992). It has been shown to mediate
type III NOS immunoreactivity on astrocytes was evident a broad range of effects on both innate and acquired
along the meninges, the parenchyma lining the 4th ventri- immunity (Trinchieri et al., 1994; Chan et al., 1991). It
cle, and the rhinal fissure (Fig. 1). Examination of brain has also been shown to be a potent activator of IFN-g
tissue at high magnification revealed the greatest densi- production (Kobayashi et al., 1989). We have observed a
ties of immunohistochemical staining on ependymal as- recovery promoting association of exogenous IL-12 on
trocytes of the central gray, brainstem, ventral tegmental VSV infection of the CNS (Bi et al., 1995b; Komatsu et
area, third ventricle, and the zonal layer of the superior al., submitted; Reiss et al., in press). Furthermore we
colliculus. Diffuse staining was also observed on astro- detected an increase in serum levels of IFN-g and TNF-
cytes of the hippocampal formation, caudate putamen, a immediately following lL-12 administration (Komatsu,
and the anterior pituitary lobe. No staining was observed Bi, and Reiss, in press). We were interested in determin-
in the cerebellum. Labelling of Type III NOS-positive as- ing if IL-12 administration would result in increased type
trocytes included cell bodies and processes (Fig. 1B). III NOS expression in vivo. Mice were injected i.p. with
either medium, 50, 100, or 200 ng IL-12 and infected (BiKinetics of type III NOS expression following VSV
et al., 1995b). On Day 4 p.i., when VSV is limited to theinfection, in vivo
olfactory bulb, brains were removed for immunohisto-
chemical examination. Staining for type III NOS revealedFollowing the intranasal administration of VSV, brain tis-
sue removed at 1, 1.5, 2, 3, 4, 6, 8, 14, and 22 days p.i. an IL-12 dose-dependent increase in expression of type
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FIG. 3. Comparison of type III NOS immunohistochemistry in CNS in uninfected and following VSV infection. (a) Olfactory bulb region obtained
from an uninfected mouse, showing type III NOS immuoreactivity. Bar, 70 nM. (b) Olfactory bulb region obtained from an infected mouse at 4 days
p.i., showing type III NOS immuoreactivity. Bar, 70 nM. (c) Brain stem region from an uninfected mouse, stained for type III NOS. Bar, 60 nM. (d)
Brain stem region from a VSV-infected mouse at Day 8 p.i., stained for type III NOS expression. Bar, 60 nM.
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FIG. 3—Continued
III NOS in astrocytes only in the virally infected olfactory the result of increased serum cytokine(s), in vitro experi-
ments using C6 cells were performed. In order to deter-bulb (Fig. 5).
mine if type III NOS activity increased following cytokine
Cytokine treatment of C6 cells increases type III NOS treatment, C6 cells were incubated with medium, IFN-g,
activity TNF-a, or IL-12 for 72 hr, and NO02 levels in culture super-
natants were measured. Treatment of C6 cells with theseIn order to examine if the increased expression of type
III NOS in astrocytes following IL-12 administration were cytokines significantly increased nitrite production in a
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FIG. 4. Expression of type III NOS following VSV infection. (a) AOB region at Day 3 p.i., bar, 10 nM. (b) caudate putamen region from a mouse
at Day 8 p.i., with arrows indicating NOS-expressing astrocytes which adjoin blood vessels. Bar, 30 nM.
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type III NOS immunoreactivity (Table 1). Both the neuro-
blastoma (NB41A3) and murine macrophage (RAW) cells
lines were employed as controls for the serologic re-
agents. There was no visible type III NOS staining on
either NB41A3 or RAW cells, which either expressed type
I NOS or type II NOS, respectively. A minor subpopulation
of C6 cells which were treated with TNF-a were found
to express type II NOS. TNF-a treatment of C6 cells may
therefore increase both the inducible (type II) and consti-
tutive (type III NOS) isoforms. However, induction of type
II NOS by TNF-amay also result from a minor subpopula-
tion by microglial cells. In contrast, all RAW cells stained
heavily with Type II NOS mAb, but failed to react with
FIG. 5. Type III NOS expression following i.p. administration of IL- Type I- or Type III-specific reagents.
12. Three mouse brains from mice infused with 50, 100, or 200 ng were
stained with anti-ecNOS antibody. Type III NOS-positive astrocytes in NO02 release is Ca
2/-dependent
the OB were counted and expressed as the average of the total of
three mice with standard deviation. Mice receiving 100 and 200 ng IL- In order to confirm that the increased levels of nitrate
12 had a statistically signifigant difference in the number of type III produced by C6 cells following cytokine treatment was
NOS-positive cells from that of the control group, as determined by the
due to the calcium-dependent Type III NOS-expressingStudent’s t test (P  0.05).
C6 cells, and not to the minor Type II contaminating
microglial population, C6 cells were cultured with and
dose-dependent manner (Fig. 6a) and was reversed in without 100 nM of the chealator EDTA. The IFN-g-induc-
the presence of the NOS inhibitor, L-NMA (Fig. 6b). A ible activity was found to be associated exclusively with
synergistic effect of IFN-g and TNF-a on nitrite produc- Ca2/ in media (Table 2). In contrast, NOS activity of RAW
tion in C6 cells was found. IL-12 treatment alone resulted cells is indifferent to the presence of the cation.
in the highest nitrite readings. This data is consistent
with the presence of a receptor for IL-12 on C6 cells. DISCUSSION
Whether IL-12 directly increases nitrite production or
This is the first report describing the presence of typewhether it is dependent on an inducible pathway is un-
III NOS expression in resident astrocytes of the CNS,known at this time.
and an increase in its immunoreactivity following viral
infection (Figs. 1– 4). Previous reports on type III NOSKinetics of the induction of type III NOS activity in C6
immunohistochemistry in the CNS have failed to makecells
this observation.
To determine the time course of activation of NO02 We believe that the distinction may lie in the method
production in C6 cells, replicate cultures were made with of preparing tissue for immunohistochemical staining.
medium, IL-2, IL-12, or IFN-g, and aliquots of supernatant We obtained type III NOS staining on astrocytes when
were harvested at 12-hr intervals for up to 72 hr. IL-12 brain tissue was briefly fixed in neutral-buffered formalin
immediately induces enzyme activity (Fig. 7). The effect (1 min). Dinerman has demonstrated the colocalization
of IFN-g is delayed, being found at the latter end of the of type III NOS staining to CA1 hippocampal pyrimidal
time course. Treatment of C6 cells with TNF-a (1 –10 ng) cells, only when glutaraldehyde-containing fixatives were
results in a similar kinetics and magnitude of induction used (Dinerman et al., 1994).
of nitrate production as is seen with IFN-g treatment (not Expression of type III NOS on astrocytes may have
shown). No NO02 production above background was seen many important implications. More than 50% of all brain
with IL-2 treatment of the cells. capillaries have astrocytic endfeet associated with them
(White et al., 1981). Since NO is a potent vasodilator
Immunohistochemical staining of C6 glial cells
(Huang et al., 1995), type III NOS-positive astrocytes lin-
following cytokine treatment
ing the ependymal cells of the meninges, 4th ventricle,
and brain capillaries may influence vascular permeabil-In order to determine if increased levels of NO02 pro-
duction by C6 cells following cytokine treatment were ity. We have previously demonstrated that there are
blood– brain barrier (BBB) perturbations following VSVthe result of increased type III NOS activity, increased
synthesis or half-life of Type III NOS, or induction of type infection (Bi et al., 1995a) which correlated with the de-
gree of illness of the animals. The sickest animals, thoseII NOS, cytokine-treated C6 cells were stained for both
isoforms of NOS. Following treatment of C6 cells with with hind limb paralysis, had a grossly detectable disrup-
tion of the BBB. By Day 22 p.i. the BBB integrity wasIFN-g, TNF-a, or IL-12, there was a large increase in
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FIG. 6. NO02 production following cytokine treatment of C6 cells. C6 cells were incubated in triplicate with either IFN-g, TNF-a, IL-12, or IFN-g
and TNF-a for 72 hr, with (a) medium or with (b) 500 mM of the NOS inhibitor L-NMA. Nitrite concentrations were quantitated and expressed as
the average of three experiments with standard deviation. A statistically significant difference in the concentration of nitrite exists in all four cytokine-
treated groups, compared to the medium, as determined by the Student’s t test (P  0.05).
reconstituted. The increased expression of type III NOS expression, there is extensive staining of type III NOS
along numerous blood vessels (Fig. 4b).in astrocytes may be a contributory factor of VSV-associ-
ated BBB disruption. The kinetics of type III NOS increase Astrocytes are in a strategic location. They outnumber
neurons and have intimate associations with both neu-following VSV infection is related with the time course of
BBB damage. At Day 8 p.i., at the peak of type III NOS rons and endothelial cells (Kimelberg et al., 1989). Fol-
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FIG. 7. Kinetics of type III NOS activity C6 cells following cytokine treatment. C6 cells were cultured with medium, or 5 ng IFN-g, IL-2, or IL-12
for 72 hr. Aliquots of supernatants from five replicates were removed at 12-hr intervals and assayed for NO02 release.
lowing VSV infection there is significant and substantial NOS expression following VSV infection may be cytokine-
mediated. The infusion of IL-12 significantly increasedincrease in type III NOS immunoreactivity. It is possible
that NO produced by astrocytes may diffuse into neigh- type III NOS expression in the virally infected OB. Treat-
ment of C6 cells with IFN-g, TNF-a, or IL-12 increasedboring neurons and other virally infected cells. We have
previously demonstrated that NO has an inhibitory effect NO02 levels and resulted in increased type III NOS immu-
noreactivity. Inflammatory cytokines present in the virallyon VSV infection in neuroblastoma cells (Bi and Reiss,
1995) and in vivo (Komatsu et al., in press). Then it is infected CNS may trigger increased activity of type III
NOS. We predict that when the promotor region of thepossible that production of NO by astrocytes may inhibit
VSV infection in the CNS. gene is cloned and examined, characteristic cytokine
response elements will be found.We have demonstrated that the increase in type III
TABLE 1
Immunohistochemical Staining of Cell Lines
Treatment of cells // NB41A3 RAW RAW C6 C6 C6 C6
Antigen Antibody (Medium) (Medium) (IFN-g) (Medium) (IFN-g) (TNF-a) (IL-12)
Type 1 NOS mAb anti NOS-1 /// Negative Negative Negative Negative Negative Negative
Type II NOS Rabbit anti-iNOS Negative / /// Negative Negative 10% / Negative
90% negative
Type III NOS Transduction Labs Negative Negative Negative / /// /// ///
rabbit anti-ecNOS
Type III NOS ABR rabbit anti-ecNOS Negative Negative Negative / /// /// ///
Mac-1 mAb Negative // /// 6% / 6% / 6% / 6% /
94% neg. 94% neg. 94% negative 94% neg.
GFAP mAb Negative Negative Negative // /// /// ///
Neurofilament-68 mAb /// Negative Negative Negative Negative Negative Negative
Note. 5 1 104 cells were cultured on chamber slides in triplicate, with either medium, IFN-g, TNF-a, or IL-12 (each at 5 ng/ml) for 72 hr. The slides
were then reacted with the antibodies and developed with ABC-PAP and DAB as described under Material and Methods. Relative staining was graded
as follows: negative, / moderate, // intermediate, and /// intense. In the case of C6 cell staining, a minor subpopulation, approximately 10% in
each assay, reacted with anti-iNOS following TNF-a treatment and with anti-Mac-1.
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TABLE 2
Calcium Dependency of Induced Type III NOS Activity
Conditions RAW cells C6 cells
Medium 196 { 69.3 nM nitrite 45.3 { 13.0
Medium / 100 mM EDTA 134.3 { 102.5 11.7 { 2.1
5 ng IFN-g 1447.3 { 47.3 286.2 { 41.2*
5 ng IFN-g / 100 mM EDTA 1339.3 { 243.4 20.7 { 11.2*
* P  0.001.
This is the first report to demonstrate that direct incu- infection by increased activity of the constitutively ex-
pressed type III NOS form. This is consistent with previ-bation of astrocytes with IL-12 results in increased
NO02 production (Figs. 5– 7). This activity was Ca
2/-de- ous experiments demonstrating that the constitutive
forms of NOS cannot only be activated, but also resultpendent (Table 2) and was inhibitable with analogs of L-
argenine (Fig. 6). Astrocytes have recently been shown in neosynthesis following various stimuli (Verge et al.,
1992; Herdegen et al., 1993). It is tempting to speculateto produce IL-12 mRNA in vitro (Constantinescu et al.,
1995). However, it is not known whether the increase in on the role of constitutive versus inducible NOS isoforms
following viral infection of the CNS. There is an increaseNO02 production by astrocytes is the direct effect of IL-
12 or to an intermediate. The kinetic data shown in Fig. in type III NOS expression at very early time points (24
hr p.i.) following VSV infection and in virally infected re-7 suggest that an IL-12 receptor rapidly regulates Ca2/
within the cells, thereby enhancing enzyme activity. As- gions of the brain. Type II NOS is induced following VSV
infection at relatively late time points (Day 3 p.i.) and istrocytes have not been characterized as IFN-g producing
cells. However, Nitta has observed that human tumor limited to microglial and mononuclear cells (Bi et al.,
1995) and is more wide-spread anatomically than typeglial cells are capable of expressing IFN-g genes (Nitta
et al., 1994). Since C6 cells are a tumor-derived cell line, III NOS. Initially following VSV infection, constitutive NOS
may be important in mediating the earliest stages ofit is possible that some of the increase in NO02 release
associated with IL-12 treatment is through a secondary innate immunity. At later time points, type II NOS expres-
sion may also inhibit viral infection. However, becausecytokine-mediated pathway (e.g., IFN-g).
During the early stages of viral infection of the CNS of the nonspecific location of type II NOS expressing
cells, NO inducibility may have detrimental results on(24 hr p.i.) there is an increase in type III NOS expression
on astrocytes along the rim of the glomerular layer of non-virally infected neighboring cells.
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